List of bibliographic references
Number of relevant bibliographic references: 3.
List of associated KwdEn.i
Nombre de
documents | Descripteur |
|---|
| 3 | Antiviral Agents (therapeutic use) |
| 3 | Drug Therapy, Combination |
| 3 | Female |
| 3 | Hepatitis C, Chronic (drug therapy) |
| 3 | Humans |
| 3 | Male |
| 3 | Middle Aged |
| 2 | Adult |
| 2 | Antiviral Agents (administration & dosage) |
| 2 | Antiviral Agents (adverse effects) |
| 2 | Genotype |
| 2 | Hepacivirus (genetics) |
| 2 | Ribavirin (therapeutic use) |
| 2 | Treatment Outcome |
| 1 | Adolescent |
| 1 | Aged |
| 1 | Aged, 80 and over |
| 1 | Benzimidazoles (therapeutic use) |
| 1 | Carbamates (administration & dosage) |
| 1 | Carbamates (adverse effects) |
| 1 | Carbamates (therapeutic use) |
| 1 | Dose-Response Relationship, Drug |
| 1 | Drug Administration Schedule |
| 1 | Fatigue (epidemiology) |
| 1 | Fluorenes (therapeutic use) |
| 1 | Global Health |
| 1 | Headache (epidemiology) |
| 1 | Hepacivirus (classification) |
| 1 | Hepacivirus (drug effects) |
| 1 | Hepatitis C, Chronic (blood) |
| 1 | Hepatitis C, Chronic (complications) |
| 1 | Hepatitis C, Chronic (mortality) |
| 1 | Heterocyclic Compounds, 4 or More Rings (administration & dosage) |
| 1 | Heterocyclic Compounds, 4 or More Rings (adverse effects) |
| 1 | Heterocyclic Compounds, 4 or More Rings (therapeutic use) |
| 1 | Incidence |
| 1 | Interferon-alpha (adverse effects) |
| 1 | Interferon-alpha (therapeutic use) |
| 1 | Liver Cirrhosis (drug therapy) |
| 1 | Liver Cirrhosis (mortality) |
| 1 | Liver Cirrhosis (virology) |
| 1 | Macrocyclic Compounds (administration & dosage) |
| 1 | Macrocyclic Compounds (adverse effects) |
| 1 | Macrocyclic Compounds (therapeutic use) |
| 1 | Nausea (epidemiology) |
| 1 | Oligopeptides (administration & dosage) |
| 1 | Oligopeptides (adverse effects) |
| 1 | Oligopeptides (therapeutic use) |
| 1 | Polyethylene Glycols (adverse effects) |
| 1 | Polyethylene Glycols (therapeutic use) |
| 1 | RNA, Viral |
| 1 | RNA, Viral (blood) |
| 1 | Recombinant Proteins (adverse effects) |
| 1 | Recombinant Proteins (therapeutic use) |
| 1 | Ribavirin (adverse effects) |
| 1 | Sofosbuvir (administration & dosage) |
| 1 | Sofosbuvir (adverse effects) |
| 1 | Sofosbuvir (therapeutic use) |
| 1 | Sulfonamides (administration & dosage) |
| 1 | Sulfonamides (adverse effects) |
| 1 | Sulfonamides (therapeutic use) |
| 1 | Sustained Virologic Response |
| 1 | Time Factors |
| 1 | Uridine Monophosphate (analogs & derivatives) |
| 1 | Uridine Monophosphate (therapeutic use) |
| 1 | Viral Load |
| 1 | Young Adult |
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/Allemagne/Analysis
HfdIndexSelect -h $EXPLOR_AREA/Data/Allemagne/Analysis/Author.i -k "Kosh Agarwal"
HfdIndexSelect -h $EXPLOR_AREA/Data/Allemagne/Analysis/Author.i \
-Sk "Kosh Agarwal" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Allemagne/Analysis/biblio.hfd
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Asie
|area= AustralieFrV1
|flux= Allemagne
|étape= Analysis
|type= indexItem
|index= Author.i
|clé= Kosh Agarwal
}}
| This area was generated with Dilib version V0.6.33.
Data generation: Tue Dec 5 10:43:12 2017. Site generation: Tue Mar 5 14:07:20 2024 |  |
